Effect of Metoprolol in Post Alcohol Septal Ablation Patients With

Status Completed

Clinical Trial Summary

Clinical Trial Description

In this trial, the investigators will assess the effect of metoprolol in patients with hypertrophic cardiomyopathy who underwent alcohol septal ablation. The investigators will evaluate the quality of life, exercise tolerance, echocardiographic parameters and laboratory marker of heart failure and myocardial injury. The investigators will enroll 50 patients that will meet all the inclusion criteria and will agree to participate in the trial. In patients with preceding beta-blocker medication, it will be discontinued and a washout period of one month will be provided. The investigators will assess baseline characteristics and then divide patients randomly into two arms based on their date of birth (even/odd days of the month). Arm A will be given metoprolol 50 mg daily for three months, after this period the effect will be evaluated and metoprolol discontinued. A month-long washout period will follow and after an additional three months without metoprolol medication, patients will be reevaluated. Arm B will be without metoprolol for three months and will be evaluated thereafter. Then the patients will be given metoprolol 50 mg daily for three months followed by a reevaluation. The investigators will evaluate the effect of metoprolol by multiple methods at the end of the 5th and 9th months of the trial. Quality of life will be assessed by a questionnaire (The Kansas City Cardiomyopathy Questionnaire), exercise tolerance by a spiroergometry (VO2 max). A conventional echocardiographic examination and an examination focused on exercise-induced left ventricular outflow tract obstruction will be performed. The investigators will also measure NTproBNP from a blood sample as a laboratory marker of heart failure and high sensitive troponin as a marker of myocardial injury. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04133532
Study type	Interventional
Source	University Hospital, Motol
Contact
Status	Completed
Phase	Phase 4
Start date	March 5, 2020
Completion date	February 23, 2023

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03249272` - Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve	Phase 4
Recruiting	`NCT03846297` - Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy
Completed	`NCT02806479` - Hypertrophic Cardiomyopathy Pilot Study
Active, not recruiting	`NCT01225978` - Refining Information Technology Support for Genetics in Medicine	N/A
Completed	`NCT00001632` - Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease	N/A
Completed	`NCT00001534` - Long Term Effects of Enalapril and Losartan on Genetic Heart Disease	N/A
Enrolling by invitation	`NCT04050579` - OPIE in the Thin Interventricular Septum	N/A
Completed	`NCT03537183` - Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy?	N/A
Completed	`NCT02590809` - Hypertrophic Cardiomyopathy Symptom Release by BX1514M	Phase 2
Completed	`NCT00001396` - Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...	Phase 1
Active, not recruiting	`NCT03723655` - A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM	Phase 2/Phase 3
Completed	`NCT05135871` - Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects	Phase 1
Completed	`NCT04129905` - Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic Cardiomyopathies	N/A
Recruiting	`NCT03061994` - Metabolomic Study of All-age Cardiomyopathy	N/A
Completed	`NCT02234336` - Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
Recruiting	`NCT00221832` - Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases	N/A
Not yet recruiting	`NCT03706001` - Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression	N/A
Recruiting	`NCT06169358` - Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy
Not yet recruiting	`NCT04090437` - HCM-AF Ablation With ACUTUS	N/A
Completed	`NCT04402268` - Efficacy of Risk Assessment for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms